Hangzhou Alltest Biotech Co., Ltd.

Shanghai Stock Exchange 688606.SS

Hangzhou Alltest Biotech Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: 27.84

Hangzhou Alltest Biotech Co., Ltd. Price to Earnings Ratio (P/E) is 27.84 on January 14, 2025, a -3.74% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Hangzhou Alltest Biotech Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 33.22 on April 26, 2024, which is 19.31% above the current Price to Earnings Ratio (P/E).
Hangzhou Alltest Biotech Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 20.19 on July 04, 2024, which is -27.48% below the current Price to Earnings Ratio (P/E).
Hangzhou Alltest Biotech Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 26.58.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Shanghai Stock Exchange: 688606.SS

Hangzhou Alltest Biotech Co., Ltd.

CEO	Mr. Fei Gao
IPO Date	March 25, 2021
Location	China
Headquarters	#550, Yinhai Street
Employees	1,093
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Pharmaceuticals

Description

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and market of in vitro diagnostic reagents worldwide. It offers rapid diagnostic products, including women's health, infectious diseases, drugs, cancer, cardiovascular, and other five series of products. The company is based in Hangzhou, China.

Key trends

Past 5 years